Menell J S, Cesarman G M, Jacovina A T, McLaughlin M A, Lev E A, Hajjar K A
Department of Pediatrics, Weill Medical College of Cornell University, New York, NY, USA.
N Engl J Med. 1999 Apr 1;340(13):994-1004. doi: 10.1056/NEJM199904013401303.
Acute promyelocytic leukemia (APL) is associated with a hemorrhagic disorder of unknown cause that responds to treatment with all-trans-retinoic acid.
We studied a newly described receptor for fibrinolytic proteins, annexin II, in cells from patients with APL or other leukemias. We examined initial rates of in vitro generation of plasmin by tissue plasminogen activator (t-PA) in the presence of APL cells that did or did not have the characteristic translocation of APL, t(15;17). We also determined the effect of all-trans-retinoic acid on the expression of annexin II and the generation of cell-surface plasmin.
The expression of annexin II, as detected by a fluorescein-tagged antibody, was greater on leukemic cells from patients with APL than on other types of leukemic cells (mean fluorescence intensity, 6.9 and 2.9, respectively; P<0.01). The t(15;17)-positive APL cells stimulated the generation of cell-surface, t-PA-dependent plasmin twice as efficiently as the t(15;17)-negative cells. This increase in plasmin was blocked by an anti-annexin II antibody and was induced by transfection of t(15;17)-negative cells with annexin II complementary DNA. The t(15;17)-positive APL cells contained abundant messenger RNA for annexin II, which disappeared through a transcriptional mechanism after treatment with all-trans-retinoic acid.
Abnormally high levels of expression of annexin II on APL cells increase the production of plasmin, a fibrinolytic protein. Overexpression of annexin II may be a mechanism for the hemorrhagic complications of APL.
急性早幼粒细胞白血病(APL)与一种病因不明的出血性疾病相关,全反式维甲酸治疗对此病有效。
我们研究了一种新描述的纤溶蛋白受体——膜联蛋白II,该受体存在于APL患者或其他白血病患者的细胞中。我们检测了组织型纤溶酶原激活物(t-PA)在有或没有APL特征性易位t(15;17)的APL细胞存在时体外产生纤溶酶的初始速率。我们还确定了全反式维甲酸对膜联蛋白II表达及细胞表面纤溶酶生成的影响。
用荧光素标记抗体检测发现,APL患者白血病细胞上膜联蛋白II的表达高于其他类型白血病细胞(平均荧光强度分别为6.9和2.9;P<0.01)。t(15;17)阳性的APL细胞刺激细胞表面依赖t-PA的纤溶酶生成的效率是t(15;17)阴性细胞的两倍。纤溶酶的这种增加被抗膜联蛋白II抗体阻断,并且通过用膜联蛋白II互补DNA转染t(15;17)阴性细胞得以诱导。t(15;17)阳性的APL细胞含有丰富的膜联蛋白II信使RNA,用全反式维甲酸治疗后通过转录机制消失。
APL细胞上膜联蛋白II异常高表达增加了纤溶酶(一种纤溶蛋白)的产生。膜联蛋白II的过表达可能是APL出血并发症的一种机制。